{"drugs":["Ala-Cort","Ala-Scalp HP","Anusol HC","Aquanil HC","Beta HC","Cetacort","Colocort","Corta-Cap","Hydrocortisone"],"mono":{"0":{"id":"291590-s-0","title":"Generic Names","mono":"Hydrocortisone"},"1":{"id":"291590-s-1","title":"Dosing and Indications","sub":[{"id":"291590-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Allergic condition:<\/b> 20 to 240 mg per day ORALLY<\/li><li><b>Chemotherapy-induced nausea and vomiting; Prophylaxis:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Collagen disease:<\/b> 20 to 240 mg per day ORALLY<\/li><li><b>Disorder of endocrine system:<\/b> 20 to 240 mg per day ORALLY<\/li><li><b>Disorder of eye:<\/b> 20 to 240 mg ORALLY per day<\/li><li><b>Disorder of gastrointestinal tract:<\/b> 20 to 240 mg ORALLY per day<\/li><li><b>Disorder of gastrointestinal tract:<\/b> 100 mg RECTALLY nightly or until remission occurs, up to 21 days; if administration longer than 21 days is required, discontinue gradually by reducing to every other night for 2 to 3 weeks<\/li><li><b>Disorder of hematopoietic structure:<\/b> 20 to 240 mg ORALLY per day<\/li><li><b>Disorder of respiratory system:<\/b> 20 to 240 mg ORALLY per day<\/li><li><b>Disorder of skin:<\/b> 20 to 240 mg ORALLY per day<\/li><li><b>Disorder of skin:<\/b> apply TOPICALLY to affected area as a thin film 2 to 4 times daily<\/li><li><b>Exacerbation of multiple sclerosis (Acute):<\/b> 800 mg ORALLY daily for 1 wk, then 320 mg every other day for 1 month<\/li><li><b>Inflammatory disorder of musculoskeletal system:<\/b> 20 to 240 mg ORALLY per day<\/li><li><b>Neoplastic disease:<\/b> 20 to 240 ORALLY mg per day<\/li><li><b>Nephrotic syndrome, Idiopathic or due to lupus erythematosus:<\/b> 20 to 240 mg ORALLY per day<\/li><li><b>Prostate cancer:<\/b> Optimal dosing and timing not yet defined<\/li><li><b>Trichinosis, With neurologic or myocardial involvement:<\/b> 20 to 240 mg ORALLY per day<\/li><li><b>Tuberculosis of meninges, With subarachnoid or impending block:<\/b> 20 to 240 mg ORALLY per day<\/li><\/ul>"},{"id":"291590-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Disorder of skin:<\/b> apply TOPICALLY to affected area as a thin film 2 to 4 times daily<\/li><li><b>Nephrotic syndrome, Idiopathic or due to lupus erythematosus:<\/b> 240 mg\/m(2) ORALLY daily; MAX 320 mg\/day; divided 3 times\/day for 4 wk, then 160 mg\/m(2) every other day for 4 wk<\/li><\/ul>"},{"id":"291590-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> no dose adjustment necessary<\/li><li><b>hepatic impairment:<\/b> dosage adjustments may be necessary<\/li><\/ul>"},{"id":"291590-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Allergic condition<\/li><li>Collagen disease<\/li><li>Disorder of endocrine system<\/li><li>Disorder of eye<\/li><li>Disorder of gastrointestinal tract<\/li><li>Disorder of hematopoietic structure<\/li><li>Disorder of respiratory system<\/li><li>Disorder of skin<\/li><li>Exacerbation of multiple sclerosis (Acute)<\/li><li>Inflammatory disorder of musculoskeletal system<\/li><li>Neoplastic disease<\/li><li>Nephrotic syndrome, Idiopathic or due to lupus erythematosus<\/li><li>Trichinosis, With neurologic or myocardial involvement<\/li><li>Tuberculosis of meninges, With subarachnoid or impending block<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Chemotherapy-induced nausea and vomiting; Prophylaxis<\/li><li>Nonspecific lung disease, chronic<\/li><li>Prostate cancer<\/li><\/ul>"}]},"3":{"id":"291590-s-3","title":"Contraindications\/Warnings","sub":[{"id":"291590-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to hydrocortisone or any of its components<\/li><li>live or live attenuated vaccines (immunosuppressive doses)<\/li><li>systemic fungal infections<\/li><\/ul>"},{"id":"291590-s-3-10","title":"Precautions","mono":"<ul><li>cirrhosis<\/li><li>diverticulitis<\/li><li>fluid disturbances, use caution in hypertension, CHF, renal insufficiency<\/li><li>hypothyroidism<\/li><li>measles, chickenpox and other infections<\/li><li>myasthenia gravis<\/li><li>ocular herpes simplex<\/li><li>osteoporosis<\/li><li>peptic ulcer<\/li><li>pregnancy<\/li><li>psychotic tendencies<\/li><li>smallpox vaccine and other immunization<\/li><li>tuberculosis, active or latent<\/li><li>ulcerative colitis<\/li><li>untreated systemic infections<\/li><\/ul>"},{"id":"291590-s-3-11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>A (AUS)<\/li><\/ul>"},{"id":"291590-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"291590-s-4","title":"Drug Interactions","sub":[{"id":"291590-s-4-13","title":"Contraindicated","mono":"<ul>Rotavirus Vaccine, Live (established)<\/ul>"},{"id":"291590-s-4-14","title":"Major","mono":"<ul><li>Aldesleukin (theoretical)<\/li><li>Bupropion (theoretical)<\/li><li>Dasabuvir (theoretical)<\/li><li>Itraconazole (probable)<\/li><li>Ombitasvir (theoretical)<\/li><li>Paritaprevir (theoretical)<\/li><li>Piperaquine (theoretical)<\/li><li>Pixantrone (theoretical)<\/li><li>Topotecan (theoretical)<\/li><\/ul>"},{"id":"291590-s-4-15","title":"Moderate","mono":"<ul><li>Alcuronium (probable)<\/li><li>Atracurium (probable)<\/li><li>Balofloxacin (established)<\/li><li>Besifloxacin (established)<\/li><li>Ciprofloxacin (established)<\/li><li>Colestipol (probable)<\/li><li>Enoxacin (established)<\/li><li>Fleroxacin (established)<\/li><li>Flumequine (established)<\/li><li>Gallamine (probable)<\/li><li>Gatifloxacin (established)<\/li><li>Gemifloxacin (established)<\/li><li>Hexafluorenium (probable)<\/li><li>Levofloxacin (established)<\/li><li>Licorice (probable)<\/li><li>Lomefloxacin (established)<\/li><li>Metocurine (probable)<\/li><li>Moxifloxacin (established)<\/li><li>Nadifloxacin (established)<\/li><li>Norfloxacin (established)<\/li><li>Ofloxacin (established)<\/li><li>Pazufloxacin (established)<\/li><li>Pefloxacin (established)<\/li><li>Primidone (probable)<\/li><li>Prulifloxacin (established)<\/li><li>Rifapentine (probable)<\/li><li>Rufloxacin (established)<\/li><li>Saiboku-To (probable)<\/li><li>Sparfloxacin (established)<\/li><li>Tosufloxacin (established)<\/li><\/ul>"}]},"5":{"id":"291590-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Musculoskeletal:<\/b>Osteoporosis<\/li><li><b>Psychiatric:<\/b>Psychotic disorder<\/li><\/ul><b>Serious<\/b><ul><li><b>Endocrine metabolic:<\/b>Cushing's syndrome, Hyperglycemia<\/li><li><b>Ophthalmic:<\/b>Cataract, Glaucoma<\/li><li><b>Respiratory:<\/b>Pulmonary tuberculosis<\/li><\/ul>"},"6":{"id":"291590-s-6","title":"Drug Name Info","sub":{"0":{"id":"291590-s-6-17","title":"US Trade Names","mono":"<ul><li>Ala-Cort<\/li><li>Ala-Scalp HP<\/li><li>Anusol HC<\/li><li>Aquanil HC<\/li><li>Beta HC<\/li><li>Cetacort<\/li><li>Colocort<\/li><li>Corta-Cap<\/li><\/ul>"},"2":{"id":"291590-s-6-19","title":"Class","mono":"<ul><li>Adrenal Glucocorticoid<\/li><li>Anti-Inflammatory<\/li><li>Corticosteroid, Weak<\/li><li>Endocrine-Metabolic Agent<\/li><li>Gastrointestinal Agent<\/li><li>Otic Agent<\/li><\/ul>"},"3":{"id":"291590-s-6-20","title":"Regulatory Status","mono":"RX\/OTC<br\/>"},"4":{"id":"291590-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"291590-s-7","title":"Mechanism Of Action","mono":"Hydrocortisone, a naturally occurring glucocorticoid (adrenal corticosteroid) acts as an anti-inflammatory, antipruritic, vasoconstrictive agent, and has salt-retaining properties. It is also used as replacement therapy in states of adrenocortical deficiency.<br\/>"},"8":{"id":"291590-s-8","title":"Pharmacokinetics","sub":[{"id":"291590-s-8-23","title":"Absorption","mono":"<ul><li>Rectal: partially absorbed<\/li><li>Bioavailability: (retention enema), 50%<\/li><\/ul>"},{"id":"291590-s-8-24","title":"Distribution","mono":"Corticosteroids, Protein binding: bound to plasma protein <br\/>"},{"id":"291590-s-8-25","title":"Metabolism","mono":"Hepatic <br\/>"},{"id":"291590-s-8-26","title":"Excretion","mono":"Renal and biliary <br\/>"}]},"9":{"id":"291590-s-9","title":"Administration","mono":"<ul><li><b>Oral<\/b><br\/>when taking large doses, take with meals and take antacids between meals<br\/><\/li><li><b>Rectal<\/b><br\/>administer while patient lies on left side and for 30 minutes thereafter, retain for at least 1 hour and preferably all night; antidiarrheals and prior sedation may be used<br\/><\/li><li><b>Topical<\/b><br\/><ul><li>(lotion) shake well before use; apply a thin film to the affected area; occlusive dressings may be used for psoriasis or recalcitrant condition<\/li><li>(cream and ointment) apply a thin film to the affected area; occlusive dressings may be used for psoriasis or recalcitrant condition<\/li><\/ul><\/li><\/ul>"},"10":{"id":"291590-s-10","title":"Monitoring","mono":"<ul><li>improvement of clinical symptoms<\/li><li>blood pressure; large doses therapy<\/li><li>periodic fluid and electrolyte status determinations<\/li><li>cataract, blurred vision; long term therapy<\/li><li>growth and development; pediatric long term therapy<\/li><li>oropharnygeal candidiasis<\/li><li>urinary free cortisol test, periodic in large doses and long-term therapy<\/li><li>ACTH stimulation test; periodic in large doses and long-term therapy<\/li><\/ul>"},"11":{"id":"291590-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Oral Tablet: 5 MG, 10 MG, 20 MG<\/li><li>Rectal Cream: 2.5 %<\/li><li>Rectal Enema: 100 MG\/60 ML<\/li><li>Topical Cream: 0.5 %, 1 %, 2.5 %<\/li><li>Topical Lotion: 1 %, 2.5 %<\/li><li>Topical Ointment: 0.5 %, 1 %, 2.5 %<\/li><\/ul><\/li><li><b>Ala-Cort<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Ala-Scalp HP<\/b><br\/>Topical Lotion: 2 %<br\/><\/li><li><b>Anusol-HC<\/b><br\/>Rectal Cream: 2.5 %<br\/><\/li><li><b>Aquanil Hc<\/b><br\/>Topical Lotion: 1 %<br\/><\/li><li><b>Aveeno 1% Hydrocortisone Anti-Itch Cream<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Colocort<\/b><br\/>Rectal Enema: 100 MG\/60 ML<br\/><\/li><li><b>Corta-Cap<\/b><br\/>Topical Spray: 1 %<br\/><\/li><li><b>Cortaid Intensive Therapy<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Cortaid Maximum Strength<\/b><br\/><ul><li>Topical Cream: 1 %<\/li><li>Topical Stick: 1 %<\/li><\/ul><\/li><li><b>Cortef<\/b><br\/>Oral Tablet: 5 MG, 10 MG, 20 MG<br\/><\/li><li><b>Cortenema<\/b><br\/>Rectal Enema: 100 MG\/60 ML<br\/><\/li><li><b>Corticool Maximum Strength<\/b><br\/>Topical Gel\/Jelly: 1 %<br\/><\/li><li><b>Cotacort<\/b><br\/>Topical Lotion: 0.5 %<br\/><\/li><li><b>Dermtex-HC<\/b><br\/><ul><li>Topical Cream: 1 %<\/li><li>Topical Spray: 1 %<\/li><\/ul><\/li><li><b>Earsol-Hc<\/b><br\/>Otic Solution: 1 %<br\/><\/li><li><b>First-Hydrocortisone<\/b><br\/>Topical Kit: 10 %<br\/><\/li><li><b>Good Neighbor Pharmacy Hydrocortisone<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Good Sense Anti-Itch<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Hemorrodil<\/b><br\/>Topical Ointment: 1 %<br\/><\/li><li><b>Hydrocortisone 1% In Absorbase<\/b><br\/>Topical Ointment: 1 %<br\/><\/li><li><b>HydroSKIN<\/b><br\/><ul><li>Topical Cream: 1 %<\/li><li>Topical Lotion: 1 %<\/li><\/ul><\/li><li><b>Hytone<\/b><br\/>Topical Cream: 2.5 %<br\/><\/li><li><b>Ivy Soothe<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Microcort<\/b><br\/>Topical Lotion: 0.5 %<br\/><\/li><li><b>Mycin Scalp<\/b><br\/>Topical Liquid: 1 %<br\/><\/li><li><b>Neosporin Eczema Essentials<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Preparation H Hydrocortisone<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Proctocort<\/b><br\/>Rectal Cream: 1 %<br\/><\/li><li><b>Proctocream-HC<\/b><br\/>Topical Cream: 2.5 %<br\/><\/li><li><b>Procto-Kit 1%<\/b><br\/>Rectal Cream: 1 %<br\/><\/li><li><b>Procto-Kit 2.5%<\/b><br\/>Rectal Cream: 2.5 %<br\/><\/li><li><b>Procto-Pak<\/b><br\/>Rectal Cream: 1 %<br\/><\/li><li><b>Proctosol-HC<\/b><br\/>Topical Cream: 2.5 %<br\/><\/li><li><b>Proctozone-Hc<\/b><br\/>Rectal Cream: 2.5 %<br\/><\/li><li><b>Recort Plus<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Rite Aid Anti-Itch<\/b><br\/><ul><li>Topical Cream: 1 %<\/li><li>Topical Ointment: 1 %<\/li><\/ul><\/li><li><b>Rite Aid First Aid Anti-Itch<\/b><br\/>Topical Spray: 1 %<br\/><\/li><li><b>Rite Aid Hydrocortisone Plus 12<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Rite Aid Hydrocortisone<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Scalacort<\/b><br\/>Topical Lotion: 2 %<br\/><\/li><li><b>Scalpana<\/b><br\/>Topical Solution: 1 %<br\/><\/li><li><b>Scalpicin<\/b><br\/>Topical Solution: 1 %<br\/><\/li><li><b>Sunmark Hydrocortisone<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Texacort<\/b><br\/>Topical Solution: 2.5 %<br\/><\/li><\/ul>"},"12":{"id":"291590-s-12","title":"Toxicology","sub":[{"id":"291590-s-12-31","title":"Clinical Effects","mono":"<b>CORTICOSTEROIDS<\/b><br\/>USES: Antiinflammatory agents used to treat a variety of clinical conditions, including adrenal insufficiency, asthma, various allergy disorders, and autoimmune disorders (eg, hemolytic anemia, rheumatoid arthritis, systemic lupus erythematosus). Corticosteroids are available in oral, parenteral, inhalational, and topical formulations. PHARMACOLOGY: Multiple mechanisms of action including anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions. Anti-inflammatory effects result from decreased formation, release and activity of the mediators of inflammation (eg, kinins, histamine, liposomal enzymes, prostaglandins, leukotrienes) which reduced the initial manifestations of the inflammatory process. The immunosuppressive properties decrease the response to delayed and immediate hypersensitivity reactions (eg, type III and type IV).  The antiproliferative effects reduce hyperplastic tissue characteristic of psoriasis. TOXICOLOGY: Corticosteroids decrease calcium absorption, increase calcium excretion, and inhibit osteoblast formation, leading to a decrease in bone formation and an increase in bone resorption, thereby contributing to the development of osteoporosis. EPIDEMIOLOGY: Acute toxicity following overdose is rare. OVERDOSE: Acute ingestion is rarely a clinical problem. Acute adrenal insufficiency rarely reported after overdose. ADVERSE EFFECTS:  Cardiac dysrhythmias (ie, atrial fibrillation)(methylPREDNISolone), seizures (methylPREDNISolone), anaphylaxis. CHRONIC EXPOSURE:  Cushingoid appearance, muscle wasting and weakness, hypertension, hyperglycemia, subcapsulary cataracts and glaucoma, osteoporosis, psychosis. ABRUPT WITHDRAWAL:  Dysphoria, irritability, emotional liability, depression, fatigue,  anxiety, depersonalization, myalgia, and arthralgia.<br\/>"},{"id":"291590-s-12-32","title":"Treatment","mono":"<b>CORTICOSTEROIDS<\/b><br\/><ul><li>Support: MANAGEMENT OF TOXICITY: Treatment is symptomatic and supportive. Seizures have been reported with IV pulse methylPREDNISolone therapy. If seizures occur, administer IV benzodiazepines, barbiturates.<\/li><li>Decontamination: PREHOSPITAL: Serious toxicity is not expected after ingestion of corticosteroids alone, and prehospital gastrointestinal decontamination is not routinely required. HOSPITAL: Significant toxicity is not expected after overdose; gastrointestinal decontamination is generally not necessary. Activated charcoal should be considered after extremely large ingestions or if more toxic coingestants are involved.<\/li><li>Airway management: Endotracheal intubation and mechanical ventilation may be required in patients with severe allergic reactions, but this is rare.<\/li><li>Antidote: None<\/li><li>Acute allergic reaction: MILD\/MODERATE: Monitor airway. Administer antihistamines with or without inhaled beta agonists, corticosteroids or epinephrine. SEVERE: Oxygen, aggressive airway management, antihistamines, epinephrine, corticosteroids, ECG monitoring and IV fluids.<\/li><li>Monitoring of patient: Routine laboratory studies are not likely to be necessary after acute overdose. Serum electrolytes and glucose are useful to assess for adverse effects from chronic therapy. Monitor vital signs, fluid and electrolyte status as indicated. Monitor neurologic status as indicated in symptomatic patients. Plasma concentrations are not readily available or clinically useful in the management of overdose.<\/li><li>Enhanced elimination procedure: Hemodialysis and hemoperfusion are UNLIKELY to be of value because of the high degree of protein binding and large volume of distribution.<\/li><li>Patient disposition: HOME CRITERIA: Patients with a minor unintentional exposure who are asymptomatic or have mild symptoms can likely be managed at home. OBSERVATION CRITERIA: Moderate to severely symptomatic patients and those with deliberate overdose should be sent to a healthcare facility for evaluation and treated until symptoms resolve. ADMISSION CRITERIA: Patients who remain symptomatic despite adequate treatment should be admitted. CONSULT CRITERIA: Consult a Poison Center for assistance in managing patients with severe toxicity or in whom the diagnosis is unclear.<\/li><\/ul>"},{"id":"291590-s-12-33","title":"Range of Toxicity","mono":"<b>CORTICOSTEROIDS<\/b><br\/>TOXICITY: Acute ingestion is rarely a clinical problem; effects rarely occur with administration of less than three weeks duration.  An adolescent ingested 30 mg dexamethasone and subsequently developed acute adrenal insufficiency. Patient recovered following administration of methylPREDNISolone. CHRONIC EXPOSURE: Six infants (aged 3 to 8 months) who were treated with large amounts (up to 10 tubes for 1.5 to 5 months) of topical corticosteroids for diaper dermatitis developed Cushing's syndrome and adrenocortical insufficiency. Hepatomegaly and hepatosteatosis were observed in 5 and 3 patients, respectively. THERAPEUTIC DOSE: Varies with drug and indication.<br\/>"}]},"13":{"id":"291590-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to avoid vaccines during oral therapy unless approved by healthcare professional.<\/li><li>This drug may cause impaired skin healing, decreased body growth, depression, or euphoria.<\/li><li>Patients on long-term therapy should report signs\/symptoms of infection, hyperglycemia, cataract or blurred vision, or hypothalamic-pituitary-adrenal (HPA) axis suppression (fatigue, depression, anxiety, hyperglycemia, muscle weakness, immunosuppression symptoms).<\/li><li>Patients should take large oral doses with meals and take antacids between meals.<\/li><li>With long-term oral use, advise patient against sudden discontinuation of drug.<\/li><li>Advise patients with psoriasis or recalcitrant conditions using the topical formulation that they may use occlusive dressings.<\/li><\/ul>"}}}